Bioterrorism Market 2018 – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2025

This report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

This report focuses on the global Bioterrorism status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Bioterrorism development in United States, Europe and China.

Bioterrorism is terrorism involving the intentional release or dissemination of biological agents. These agents are bacteria, viruses, fungi, or toxins, and may be in a naturally occurring or a human-modified form, in much the same way in biological warfare.
Bioterrorism refers to form of terrorism that involves intentional dissemination or release of biological agents. The agents can be viruses, bacteria or toxins and can also be referred to as germ warfare. Biological agents are mainly found in nature but sometimes they can be modified by the terrorist as to make agents more toxic. Biological agents are used by the terrorists to attain their social or political goals and are used for killing or injuring people, plants and animals. Biological weapons are dangerous as some of these agents are transmitted from one person to another and infection might take hours or days to become noticeable.
Bioterrorism is an invaluable tool as biological agents are relatively inexpensive and can cause widespread fear beyond the actual damage they can cause. They are mainly used by the terrorists to create mass panic and disruption of state or economy. The global market for bioterrorism is segmented on the type of different biological agents currently being used and their mode of delivery. Agents such as anthrax, tularemia, small pox, bubonic plague, botulinum toxin and viral hemorrhagic fevers pose a high threat to national security.
In 2017, the global Bioterrorism market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

The key players covered in this study
Bavarian Nordic
DynPort Vaccine Company (DVC)
Emergent BioSolutions
Cleveland BioLabs
Elusys Therapeutics

Request a Sample Report @

Market segment by Type, the product can be split into
Radiation/Nuclear defense

Market segment by Application, split into

Market segment by Regions/Countries, this report covers
United States
Southeast Asia
Central & South America

The study objectives of this report are:
To analyze global Bioterrorism status, future forecast, growth opportunity, key market and key players.
To present the Bioterrorism development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Bioterrorism Market Size Growth Rate by Type (2013-2025)
1.4.2 Anthrax
1.4.3 Smallpox
1.4.4 Botulism
1.4.5 Radiation/Nuclear defense
1.4.6 Others
1.5 Market by Application
1.5.1 Global Bioterrorism Market Share by Application (2013-2025)
1.5.2 Military
1.5.3 Government
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Bioterrorism Market Size
2.2 Bioterrorism Growth Trends by Regions
2.2.1 Bioterrorism Market Size by Regions (2013-2025)
2.2.2 Bioterrorism Market Share by Regions (2013-2018)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Bioterrorism Market Size by Manufacturers
3.1.1 Global Bioterrorism Revenue by Manufacturers (2013-2018)
3.1.2 Global Bioterrorism Revenue Market Share by Manufacturers (2013-2018)
3.1.3 Global Bioterrorism Market Concentration Ratio (CR5 and HHI)
3.2 Bioterrorism Key Players Head office and Area Served
3.3 Key Players Bioterrorism Product/Solution/Service
3.4 Date of Enter into Bioterrorism Market
3.5 Mergers & Acquisitions, Expansion Plans


12 International Players Profiles
12.1 Altimmune
12.1.1 Altimmune Company Details
12.1.2 Company Description and Business Overview
12.1.3 Bioterrorism Introduction
12.1.4 Altimmune Revenue in Bioterrorism Business (2013-2018)
12.1.5 Altimmune Recent Development
12.2 Bavarian Nordic
12.2.1 Bavarian Nordic Company Details
12.2.2 Company Description and Business Overview
12.2.3 Bioterrorism Introduction
12.2.4 Bavarian Nordic Revenue in Bioterrorism Business (2013-2018)
12.2.5 Bavarian Nordic Recent Development
12.3 DynPort Vaccine Company (DVC)
12.3.1 DynPort Vaccine Company (DVC) Company Details
12.3.2 Company Description and Business Overview
12.3.3 Bioterrorism Introduction
12.3.4 DynPort Vaccine Company (DVC) Revenue in Bioterrorism Business (2013-2018)
12.3.5 DynPort Vaccine Company (DVC) Recent Development
12.4 Emergent BioSolutions
12.4.1 Emergent BioSolutions Company Details
12.4.2 Company Description and Business Overview
12.4.3 Bioterrorism Introduction
12.4.4 Emergent BioSolutions Revenue in Bioterrorism Business (2013-2018)
12.4.5 Emergent BioSolutions Recent Development
12.5 Acambis
12.5.1 Acambis Company Details
12.5.2 Company Description and Business Overview
12.5.3 Bioterrorism Introduction
12.5.4 Acambis Revenue in Bioterrorism Business (2013-2018)
12.5.5 Acambis Recent Development
12.6 Achaogen
12.6.1 Achaogen Company Details
12.6.2 Company Description and Business Overview
12.6.3 Bioterrorism Introduction
12.6.4 Achaogen Revenue in Bioterrorism Business (2013-2018)
12.6.5 Achaogen Recent Development
12.7 Cleveland BioLabs
12.7.1 Cleveland BioLabs Company Details
12.7.2 Company Description and Business Overview
12.7.3 Bioterrorism Introduction
12.7.4 Cleveland BioLabs Revenue in Bioterrorism Business (2013-2018)
12.7.5 Cleveland BioLabs Recent Development
12.8 Elusys Therapeutics
12.8.1 Elusys Therapeutics Company Details
12.8.2 Company Description and Business Overview
12.8.3 Bioterrorism Introduction
12.8.4 Elusys Therapeutics Revenue in Bioterrorism Business (2013-2018)
12.8.5 Elusys Therapeutics Recent Development


Access Complete Report @

Media Contact
Company Name:
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India